ASTHMA AND COPD MARKET ANALYSIS

Asthma And COPD Market, By Drug Type (Bronchodilators (Short Acting Bronchodilators, Long Acting Bronchodilators), Anti-Inflammatories (Inhaled Corticosteroids, Leukotriene Modulators and Others), Combination Therapies), By Disease Type (Asthma, and COPD), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe Asia, Pacific Middle East & Africa) -

Published In : Jul 2023
Code : CMI4002
Pages :183
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Asthma And COPD Market: Key Developments

In February 2020, Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd, a China-based biopharmaceutical company, approved to start clinical trial of new Anti-IL-5 monoclonal antibody drug for treatment of asthma in China.

In June 2020, Novartis Pharma K.K, the Japan business of strategic alliance partner Novartis AG, a Switzerland-based multinational pharmaceutical comapany, announced the manufacturing and marketing approval for its Enerzair Inhalation Capsules (medium-dose and high-dose) in Japan as a treatment of bronchial asthma.

In August 2022, Upstream Bio, a U.S.-based drug developer, initiated a Phase Ib multiple ascending dose study of UPB-101 in asthma patients and successful dosing of the first patient. UPB-101 is a monoclonal antibody designed to block the thymic stromal lymphopoietin receptor (TLSPR) and thus inhibit TSLP-driven inflammation. TSLP is a cytokine and a key driver of inflammatory response in asthma and other allergic and inflammatory diseases.

On 9 February 2022, Generium, a Russia-based pharmaceutical company, announced the launch of Omalizumab in Russia, under the brand name Genolar. Genolar is a recombinant humanized IgG1k monoclonal antibody that binds to free human immunoglobulin E (IgE). The product is available in Russia for the treatment of persistent atopic bronchial asthma (the most common form of asthma) in patients aged 6 and older.